Home Biosimilar Antibodies Immunology & Inflammation CD markers Ragifilimab (Anti-TNFRSF18 / GITR / CD357)
For research use only. Not for use in humans.

Ragifilimab (Anti-TNFRSF18 / GITR / CD357)

Synonyms: TNFRSF18， CD357

Ragifilimab (Anti-TNFRSF18 / GITR / CD357) is an anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR; CD357) agonistic humanized monoclonal antibody with potential immune checkpoint modulating activity. MW : 145.5 KD.

Ragifilimab (Anti-TNFRSF18 / GITR / CD357)

Quality Control

Batch: A232701 Purity: 99% Protein concentration: 14.22mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Ragifilimab (Anti-TNFRSF18 / GITR / CD357) is an anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR; CD357) agonistic humanized monoclonal antibody with potential immune checkpoint modulating activity. MW : 145.5 KD.

Product Details

CAS No. 2207590-51-8
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04470024 ACTIVE_NOT_RECRUITING Drug: INCAGN01876|Drug: INCMGA00012 Cancer of the Head and Neck Providence Health & Services 2021-08-05 PHASE1
NCT04021043 COMPLETED Drug: Anti-GITR Agonistic Monoclonal Antibody BMS-986156 Advanced Malignant Solid Neoplasm; Metastatic Carcinoma in the Liver; Metastatic Carcinoma in the Lung; Metastatic Malignant Neoplasm in the Thoracic Cavity; Metastatic Malignant Solid Neoplasm M.D. Anderson Cancer Center 2019-08-19 PHASE1; PHASE2
NCT04465487 TERMINATED Drug: REGN6569|Drug: Cemiplimab Squamous Cell Carcinoma of Head and Neck Regeneron Pharmaceuticals 2020-10-05 PHASE1
NCT03799003 TERMINATED Drug: ASP1951|Drug: pembrolizumab Advanced Solid Tumors Astellas Pharma Global Development, Inc. 2019-01-14 PHASE1
NCT04225039 ACTIVE_NOT_RECRUITING Drug: INCMGA00012|Drug: INCAGN01876|Drug: SRS Glioblastoma University of Pennsylvania 2020-06-23 PHASE2
NCT02740270 COMPLETED Drug: GWN323|Drug: PDR001 Solid Tumors; Lymphomas Novartis Pharmaceuticals 2016-07-22 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-09-03)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.